Oncologists share their treatment preferences for patients with advanced NSCLC with EGFR mutations. Improving survival and ...

The carboplatin-pemetrexed doublet was well tolerated in the present as well as in the previous studies. [19–21] When comparing the present study with the aforementioned studies, we observe that ...

In February 2004, pemetrexed disodium (Alimta; Eli Lilly), an anticancer drug that targets folate-dependent reactions that are essential for cell proliferation, became the first drug to be ...

Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung ...

HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but the BLA for HER3-DXd has been withdrawn.

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...

Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ ...

MK-1084, Merck’s investigational KRAS G12C inhibitor, showed a manageable safety profile along with antitumor activity in the ...

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...